세계의 항진균제 시장 - 산업 규모, 점유율, 동향, 기회, 예측 : 약제 클래스별, 적응증별, 감염 유형별, 투여 경로별, 최종 사용자별, 유통 채널별, 지역별, 경쟁별(2020-2030년)
Anti-Fungal Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Class, By Indication, By Infection Type, By Route of Administration, By End User, By Distribution Channel, By Region and Competition, 2020-2030F
상품코드:1785156
리서치사:TechSci Research
발행일:2025년 08월
페이지 정보:영문 185 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
세계의 항진균제 시장은 2024년에 124억 7,000만 달러로 평가되었으며, 2030년까지의 CAGR은 4.33%를 나타내 예측 기간 동안 눈부신 성장을 이룰 것으로 예상되고 있습니다.
진균 감염의 치료에는 항진균제가 일반적으로 처방됩니다. 이러한 약물은 경구 투여, 국소 투여, 점적에 의한 정맥내 투여가 가능합니다. 효모 감염, 백선, 손톱 및 피부 질환과 같은 곰팡이 감염은 토양, 공기 및 피부에 존재하는 곰팡이에 의해 발생할 수 있습니다. 또한 곰팡이 포자를 흡입하면 호흡기 시스템의 문제로 이어질 수 있습니다. 따라서 면역력이 저하된 사람은 곰팡이 감염에 걸리기 쉽고 항진균제의 사용이 필요합니다. 이 약의 대부분은 의사의 처방전이 필요하지만 일부는 시판 중입니다.
시장 개요
예측 기간
2026-2030년
시장 규모 : 2024년
124억 7,000만 달러
시장 규모 : 2030년
161억 1,000만 달러
CAGR : 2025-2030년
4.33%
급성장 부문
아졸
최대 시장
북미
항진균제에는 크게 국소성과 전신성의 2유형이 있습니다. 치료하는 증상에 따라, 국소 항진균제는 일반적으로 국소 또는 질에 적용되고, 전신 항진균제는 경구 또는 정맥 내로 투여됩니다. 전신 투여제의 예로는 이트라코나졸, 플루코나졸, 케토코나졸, 볼리코나졸, 포사코나졸, 이사코나졸 등이 있습니다. 항진균제에는 진균 세포를 직접 사멸시키는 방법과 진균 세포의 증식과 개발을 저해하는 방법의 두 가지가 있습니다. 또한 항진균제는 진균 세포에는 필수이지만 인간 세포에는 없는 구조나 기능을 표적으로 함으로써 인간 세포를 손상시키지 않고 진균 감염과 싸울 수 있습니다. 곰팡이의 세포막과 세포벽은 곰팡이 세포를 둘러싸고 보호하기 때문에 종종 표적이되는 성분입니다. 이러한 구조 중 하나가 손상되면 곰팡이 세포가 파열되어 사멸합니다.
주요 시장 성장 촉진요인
진균 감염의 유병률 상승
주요 시장 과제
건강에 부정적인 영향
주요 시장 동향
연구개발수 증가
목차
제1장 개요
제2장 조사 방법
제3장 주요 요약
제4장 고객의 목소리
제5장 세계의 항진균제 시장 전망
시장 규모와 예측
금액별
시장 점유율·예측
약제 클래스별(아졸, 에키노칸딘, 폴리엔, 알릴아민, 기타)
적응증별(칸디다증, 아스페르길루스증, 점막 진균증, 피부 진균증, 기타)
감염 유형별(표재성 진균 감염증, 전신성 진균 감염증)
투여 경로별(국소, 경구, 비경구, 기타)
최종 사용자별(재택 케어, 병원, 진료소, 기타)
유통 채널별(소매 약국, 병원 약국, 온라인 약국)
지역별
기업별(2024년)
시장 맵
제6장 북미의 항진균제 시장 전망
시장 규모와 예측
시장 점유율·예측
북미 : 국가별 분석
미국
캐나다
멕시코
제7장 유럽의 항진균제 시장 전망
시장 규모와 예측
시장 점유율·예측
유럽 : 국가별 분석
독일
영국
이탈리아
프랑스
스페인
제8장 아시아태평양의 항진균제 시장 전망
시장 규모와 예측
시장 점유율·예측
아시아태평양 : 국가별 분석
중국
인도
일본
한국
호주
제9장 남미의 항진균제 시장 전망
시장 규모와 예측
시장 점유율·예측
남미 : 국가별 분석
브라질
아르헨티나
콜롬비아
제10장 중동 및 아프리카의 항진균제 시장 전망
시장 규모와 예측
시장 점유율·예측
중동 및 아프리카 : 국가별 분석
남아프리카
사우디아라비아
아랍에미리트(UAE)
제11장 시장 역학
성장 촉진요인
과제
제12장 시장 동향과 발전
최근 동향
합병과 인수
제품 출시
제13장 세계의 항진균제 시장 : SWOT 분석
제14장 Porter's Five Forces 분석
업계 내 경쟁
신규 진입의 가능성
공급자의 힘
고객의 힘
대체품의 위협
제15장 경쟁 구도
Abbott Laboratories Inc.
Astellas Pharma Inc.
Bayer AG
GSK plc
Glenmark Pharmaceuticals Limited
Merck & Co. Inc.
Novartis AG
Pfizer Inc.
Mycovia Pharmaceuticals, Inc.
Apex Laboratories Pvt. Ltd.
제16장 전략적 제안
제17장 기업 소개와 면책사항
KTH
영문 목차
영문목차
Global Anti-Fungal Drugs Market was valued at USD 12.47 Billion in 2024 and is anticipated to project impressive growth in the forecast period with a CAGR of 4.33% through 2030. Antifungal medications are commonly prescribed to treat fungal infections. These medications can be administered orally, topically, or intravenously via an IV drip. Fungal infections such as yeast infections, ringworm, nail and skin diseases can be caused by fungi present in the soil, air, and skin. Inhaling fungal spores may also lead to respiratory issues. Therefore, individuals with weakened immune systems are more susceptible to fungal infections, necessitating the use of antifungal medication. Most of these medications require a doctor's prescription, although a few are available over the counter.
Market Overview
Forecast Period
2026-2030
Market Size 2024
USD 12.47 Billion
Market Size 2030
USD 16.11 Billion
CAGR 2025-2030
4.33%
Fastest Growing Segment
Azoles
Largest Market
North America
There are two main categories of antifungal drugs: local and systemic. Depending on the specific condition being treated, local antifungals are commonly applied topically or vaginally, while systemic antifungals are administered orally or intravenously. Examples of systemically administered medicines include itraconazole, fluconazole, ketoconazole, voriconazole, posaconazole, and isavuconazole. Antifungal medications can function in one of two ways: they can directly kill fungal cells or inhibit their growth and development. Moreover, antifungal medications work by targeting structures or functions that are essential in fungal cells but not in human cells, allowing them to combat fungal infections without harming human cells. The fungal cell membrane and cell wall are frequently targeted components, as they surround and protect the fungal cell. Compromising either of these structures can cause the fungal cell to burst open and die.
Key Market Drivers
Rising Prevalence of Fungal Infections
The increasing prevalence of fungal infections is a key driver for the revenue growth in the market. Research indicates that fungal pathogens are responsible for approximately 13 million infections and 1.5 million deaths worldwide each year. Antifungal medications are also administered orally. On March 30, 2023, GSK plc and SCYNEXIS, Inc. announced an exclusive license agreement for Brexafemme, a first-in-class antifungal approved by the U.S. Food and Drug Administration (FDA) for the treatment of Vulvovaginal Candidiasis (VVC) and the reduction of the incidence of recurrent VVC (RVVC). This exclusive licensing deal grants GSK the sole right to commercialize Brexafemme for VVC and RVVC while continuing the development of ibrexafungerp, which is currently in phase III clinical trials for the possible treatment of Invasive Candidiasis (IC), a potentially fatal fungal infection.
The prevalence of fungal infections has been on the rise in recent years, prompting concerns within the healthcare industry. Contributing factors to this alarming trend include increasing global temperatures, the prevalence of chronic illnesses, and compromised immune systems. Hospital-acquired fungal infections, or nosocomial infections, have become a significant concern, with approximately 1.7 million hospitalized patients contracting such infections in 2019, according to the Centers for Disease Control and Prevention (CDC).
Key Market Challenges
Adverse Health Effects
There are several disadvantages associated with antifungal drugs. One key factor is that individuals with weakened immune systems, such as those with acquired immunodeficiency syndrome (AIDS), lupus, cancer, and other conditions, are more susceptible to dangerous fungal infections known as opportunistic infections. This vulnerability poses a challenge to the revenue growth of the antifungal drug market.
Furthermore, the type of medicine, dosage strength, and the specific fungus being treated can all influence the outcome of the medication. Common side effects may include pain in the abdomen, unsettled stomach, diarrhea, and itchy, scorching, or rashy skin. These symptoms can also have a negative impact on the revenue growth of the market.
In addition to these challenges, antifungal medication can produce major side effects, including liver damage such as jaundice, anaphylaxis, and other severe allergic responses. Blisters and peeling skin are also symptoms of severe allergic skin reactions that can occur as a result of using antifungal drugs. Considering these factors, it becomes evident that while antifungal drugs are necessary for treating fungal infections, they do come with significant drawbacks that need to be taken into account.
Key Market Trends
Increase In the Number of Research and Development Activities
The increase in the number of research and development (R&D) activities in the field of antifungal drugs is expected to significantly boost the demand for these medications. Antifungal drugs are critical for treating a wide range of fungal infections, from superficial conditions like athlete's foot to life-threatening systemic infections. Increasing R&D investments lead to the discovery of new antifungal compounds and formulations. These innovations are likely to result in the development of more effective drugs with improved mechanisms of action, enhancing the arsenal of treatment options available. R&D efforts are dedicated to understanding and combating antifungal resistance. Researchers are working to identify the mechanisms behind resistance and develop strategies to overcome it. This will ensure the continued effectiveness of antifungal drugs, driving their demand. Research in the field of fungal biology is uncovering specific molecular targets within fungal cells that can be exploited for drug development. Targeted therapies can enhance drug efficacy and reduce side effects, making antifungal drugs more appealing to healthcare providers and patients.
Key Market Players
Abbott Laboratories Inc.
Astellas Pharma Inc.
Bayer AG
GSK plc
Glenmark Pharmaceuticals Limited
Merck & Co. Inc.
Novartis AG
Pfizer Inc.
Mycovia Pharmaceuticals, Inc.
Apex Laboratories Pvt. Ltd.
Report Scope:
In this report, the Global Anti-Fungal Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Anti-Fungal Drugs Market, By Drug Class:
Azoles
Echinocandins
Polyenes
Allylamines
Others
Anti-Fungal Drugs Market, By Indication:
Candidiasis
Aspergillosis
Mucormycosis
Dermatophytosis
Others
Anti-Fungal Drugs Market, By Infection Type:
Superficial Fungal Infection
Systemic Fungal Infection
Anti-Fungal Drugs Market, By Route of Administration:
Topical
Oral
Parenteral
Others
Anti-Fungal Drugs Market, By End User:
Homecare
Hospitals
Clinics
Others
Anti-Fungal Drugs Market, By Distribution Channel:
Retail Pharmacy
Hospital Pharmacy
Online Pharmacy
Anti-Fungal Drugs Market, By Region:
North America
United States
Canada
Mexico
Europe
France
United Kingdom
Italy
Germany
Spain
Asia-Pacific
China
India
Japan
Australia
South Korea
South America
Brazil
Argentina
Colombia
Middle East & Africa
South Africa
Saudi Arabia
UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Anti-Fungal Drugs Market.
Available Customizations:
Global Anti-Fungal Drugs market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validations
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Anti-Fungal Drugs Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Drug Class (Azoles, Echinocandins, Polyenes, Allylamines, Others)
5.2.2. By Indication (Candidiasis, Aspergillosis, Mucormycosis, Dermatophytosis, Others)
5.2.3. By Infection Type (Superficial Fungal Infection, Systemic Fungal Infection)
5.2.4. By Route of Administration (Topical, Oral, Parenteral, Others)
5.2.5. By End User (Homecare, Hospitals, Clinics, Others)
5.2.6. By Distribution Channel (Retail Pharmacy, Hospital Pharmacy, Online Pharmacy)
5.2.7. By Region
5.2.8. By Company (2024)
5.3. Market Map
6. North America Anti-Fungal Drugs Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Drug Class
6.2.2. By Indication
6.2.3. By Infection Type
6.2.4. By Route Of Administration
6.2.5. By End User
6.2.6. By Distribution Channel
6.2.7. By Country
6.3. North America: Country Analysis
6.3.1. United States Anti-Fungal Drugs Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Drug Class
6.3.1.2.2. By Indication
6.3.1.2.3. By Infection Type
6.3.1.2.4. By Route Of Administration
6.3.1.2.5. By End User
6.3.1.2.6. By Distribution Channel
6.3.2. Canada Anti-Fungal Drugs Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Drug Class
6.3.2.2.2. By Indication
6.3.2.2.3. By Infection Type
6.3.2.2.4. By Route Of Administration
6.3.2.2.5. By End User
6.3.2.2.6. By Distribution Channel
6.3.3. Mexico Anti-Fungal Drugs Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Drug Class
6.3.3.2.2. By Indication
6.3.3.2.3. By Infection Type
6.3.3.2.4. By Route Of Administration
6.3.3.2.5. By End User
6.3.3.2.6. By Distribution Channel
7. Europe Anti-Fungal Drugs Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Drug Class
7.2.2. By Indication
7.2.3. By Infection Type
7.2.4. By Route Of Administration
7.2.5. By End User
7.2.6. By Distribution Channel
7.2.7. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Anti-Fungal Drugs Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Drug Class
7.3.1.2.2. By Indication
7.3.1.2.3. By Infection Type
7.3.1.2.4. By Route Of Administration
7.3.1.2.5. By End User
7.3.1.2.6. By Distribution Channel
7.3.2. United Kingdom Anti-Fungal Drugs Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Drug Class
7.3.2.2.2. By Indication
7.3.2.2.3. By Infection Type
7.3.2.2.4. By Route Of Administration
7.3.2.2.5. By End User
7.3.2.2.6. By Distribution Channel
7.3.3. Italy Anti-Fungal Drugs Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecasty
7.3.3.2.1. By Drug Class
7.3.3.2.2. By Indication
7.3.3.2.3. By Infection Type
7.3.3.2.4. By Route Of Administration
7.3.3.2.5. By End User
7.3.3.2.6. By Distribution Channel
7.3.4. France Anti-Fungal Drugs Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Drug Class
7.3.4.2.2. By Indication
7.3.4.2.3. By Infection Type
7.3.4.2.4. By Route Of Administration
7.3.4.2.5. By End User
7.3.4.2.6. By Distribution Channel
7.3.5. Spain Anti-Fungal Drugs Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Drug Class
7.3.5.2.2. By Indication
7.3.5.2.3. By Infection Type
7.3.5.2.4. By Route Of Administration
7.3.5.2.5. By End User
7.3.5.2.6. By Distribution Channel
8. Asia-Pacific Anti-Fungal Drugs Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Drug Class
8.2.2. By Indication
8.2.3. By Infection Type
8.2.4. By Route Of Administration
8.2.5. By End User
8.2.6. By Distribution Channel
8.2.7. By Country
8.3. Asia-Pacific: Country Analysis
8.3.1. China Anti-Fungal Drugs Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Drug Class
8.3.1.2.2. By Indication
8.3.1.2.3. By Infection Type
8.3.1.2.4. By Route Of Administration
8.3.1.2.5. By End User
8.3.1.2.6. By Distribution Channel
8.3.2. India Anti-Fungal Drugs Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Drug Class
8.3.2.2.2. By Indication
8.3.2.2.3. By Infection Type
8.3.2.2.4. By Route Of Administration
8.3.2.2.5. By End User
8.3.2.2.6. By Distribution Channel
8.3.3. Japan Anti-Fungal Drugs Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Drug Class
8.3.3.2.2. By Indication
8.3.3.2.3. By Infection Type
8.3.3.2.4. By Route Of Administration
8.3.3.2.5. By End User
8.3.3.2.6. By Distribution Channel
8.3.4. South Korea Anti-Fungal Drugs Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Drug Class
8.3.4.2.2. By Indication
8.3.4.2.3. By Infection Type
8.3.4.2.4. By Route Of Administration
8.3.4.2.5. By End User
8.3.4.2.6. By Distribution Channel
8.3.5. Australia Anti-Fungal Drugs Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Drug Class
8.3.5.2.2. By Indication
8.3.5.2.3. By Infection Type
8.3.5.2.4. By Route Of Administration
8.3.5.2.5. By End User
8.3.5.2.6. By Distribution Channel
9. South America Anti-Fungal Drugs Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Drug Class
9.2.2. By Indication
9.2.3. By Infection Type
9.2.4. By Route Of Administration
9.2.5. By End User
9.2.6. By Distribution Channel
9.2.7. By Country
9.3. South America: Country Analysis
9.3.1. Brazil Anti-Fungal Drugs Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Drug Class
9.3.1.2.2. By Indication
9.3.1.2.3. By Infection Type
9.3.1.2.4. By Route Of Administration
9.3.1.2.5. By End User
9.3.1.2.6. By Distribution Channel
9.3.2. Argentina Anti-Fungal Drugs Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Drug Class
9.3.2.2.2. By Indication
9.3.2.2.3. By Infection Type
9.3.2.2.4. By Route Of Administration
9.3.2.2.5. By End User
9.3.2.2.6. By Distribution Channel
9.3.3. Colombia Anti-Fungal Drugs Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Drug Class
9.3.3.2.2. By Indication
9.3.3.2.3. By Infection Type
9.3.3.2.4. By Route Of Administration
9.3.3.2.5. By End User
9.3.3.2.6. By Distribution Channel
10. Middle East and Africa Anti-Fungal Drugs Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Drug Class
10.2.2. By Indication
10.2.3. By Infection Type
10.2.4. By Route Of Administration
10.2.5. By End User
10.2.6. By Distribution Channel
10.2.7. By Country
10.3. MEA: Country Analysis
10.3.1. South Africa Anti-Fungal Drugs Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Drug Class
10.3.1.2.2. By Indication
10.3.1.2.3. By Infection Type
10.3.1.2.4. By Route Of Administration
10.3.1.2.5. By End User
10.3.1.2.6. By Distribution Channel
10.3.2. Saudi Arabia Anti-Fungal Drugs Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Drug Class
10.3.2.2.2. By Indication
10.3.2.2.3. By Infection Type
10.3.2.2.4. By Route Of Administration
10.3.2.2.5. By End User
10.3.2.2.6. By Distribution Channel
10.3.3. UAE Anti-Fungal Drugs Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Drug Class
10.3.3.2.2. By Indication
10.3.3.2.3. By Infection Type
10.3.3.2.4. By Route Of Administration
10.3.3.2.5. By End User
10.3.3.2.6. By Distribution Channel
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Recent Development
12.2. Mergers & Acquisitions
12.3. Product Launches
13. Global Anti-Fungal Drugs Market: SWOT Analysis
